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Abstract
The mutation rate of the mitochondrial DNA (mtDNA), which is higher by an order of magnitude as compared with the nuclear
genome, enforces tight mitonuclear coevolution to maintain mitochondrial activities. Interruption of such coevolution plays a role in
interpopulation hybrid breakdown, speciation events, and disease susceptibility. Previously, we found an elevated amino acid re-
placement rateandpositive selection in thenuclearDNA-encodedoxidativephosphorylation (OXPHOS) complex I subunitNDUFC2, a
phenomenon important for the direct interaction ofNDUFC2with the mtDNA-encoded complex I subunitND4. This finding under-
lines the importance of mitonuclear coevolution to physical interactions between mtDNA and nuclear DNA-encoded factors.
Nevertheless, it remains unclear whether this interaction is important for the stability and activity of complex I. Here, we show
that siRNA silencing ofNDUFC2 reduced growth of human D-407 retinal pigment epithelial cells, significantly diminished mitochon-
drial membrane potential, and interfered with complex I integrity. Moreover, site-directed mutagenesis of a positively selected amino
acid inNDUFC2 significantly interfered with the interaction ofNDUFC2with its mtDNA-encoded partnerND4. Finally,we show that a
genotype combination involving this amino acid (NDUFC2 residue 46) and the mtDNA haplogroup HV likely altered susceptibility to
type 2 diabetes mellitus in Ashkenazi Jews. Therefore, mitonuclear coevolution is important for maintaining mitonuclear factor
interactions, OXPHOS, and for human health.
Key words: coevolution, complex I, mitonuclear interaction, mitochondria, mtDNA, NDUFC2.
Introduction
The mitochondrion is the major source of cellular energy and
its function is critical to the life of higher organisms.
Mitochondria is especially important for the routine function
of energetic tissues, such as the central and peripheral nervous
systems, skeletal muscle, heart, liver, and pancreas (Zeviani
and Di Donato 2004; Schapira 2006). Early in eukaryotic evo-
lution, the once independently living mitochondrial ancestor
lost most of its coding sequences to the host (Gray 2012). As a
result, most of the ~1,500 genes required for mitochondrial
function (in humans) are encoded by the nucleus, whereas
37 genes are encoded by the maternally inherited circular
mitochondrial DNA (mtDNA) (Calvo and Mootha 2010).
The latter includes genes for 13 proteins of the adenosine
three phosphate (ATP)-producing oxidative phosphorylation
(OXPHOS) system, 2 rRNA genes (12S, 16S), and 22 tRNA
genes. The protein-coding genes include those directing the
synthesis of seven subunits (ND1–6, ND4L) of the NADH ubi-
quinone oxidoreductase (complex I), one subunit (Cyt b) of the
ubiquinol cytochrome c reductase (complex III), three subunits
GBE
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(CO1–3) of the cytochrome c oxidase (complex IV), and two
subunits (ATP6,8) of the F1-F0 ATP synthase (complex V).
Given that mitochondria play a central role in energy produc-
tion, it is not surprising that mitochondrial dysfunction affects
cell metabolism (Ritov et al. 2010).
The fast rate of mtDNA change imposes tight coevolution of
closely interacting mtDNA-encoded factors and nuclear DNA
(nDNA)-encoded factors (Grossman et al. 2004; Bar-Yaacov
et al. 2012; Dowling 2014). Accordingly, it was shown that
interfering with mitonuclear coevolution leads to hybrid break-
down and reduces fitness due to OXPHOS dysfunction (Burton
et al. 2006; Lee et al. 2008; Barreto and Burton 2013; Hoekstra
et al. 2013; Meiklejohn et al. 2013). This led us to propose that
mitonuclear incompatibility played a major role in the creation
of reproductive barriers and even speciation events (Gershoni
et al. 2009). In addition to the involvement of mitonuclear ep-
istatic interactions in long-term evolutionary processes, it has
been shown that certain mtDNA–nDNA genotype combina-
tions affect the penetrance of genetic disorders (Johnson
etal.2001;Hudsonetal.2005;Potlurietal.2009)and longevity
(Zhu et al. 2014). Because most mitonuclear interactions occur
between OXPHOS complex I components, there is major inter-
est in assessing the involvement of such interactions in disease.
Several pieces of evidence underline the importance of
complex I mitonuclear interactions in evolution and disease.
First, cells harboring mitochondria from chimpanzee or gorilla
and human nuclei display a specific ~40% reduction in com-
plex I activity (Barrientos et al. 1998). Second, Potluri et al.
(2009) found that the phenotypic impact of a mutation in
the nDNA-encoded subunit NDUFA1 that causes progressive
complex I-specific neurodegenerative disease was modulated
by mtDNA genetic backgrounds (Potluri et al. 2009).
Accordingly, NDUFA1 was found to directly interact with
two complex I mtDNA-encoded subunits (Gershoni et al.
2010). Third, Rai et al. (2007) found that a combination be-
tween the A10398G nonsynonymous change in mtDNA-
encoded complex I subunit ND3 with nDNA-encoded variants
increased susceptibility to developing type 2 diabetes mellitus
(T2DM). Finally, we found that genetic association of T2DM
with the mtDNA genetic background haplogroup J1, which is
mainly defined by nonsynonymous changes in complex I sub-
units, was modulated by nuclear genetic factors (Feder et al.
2009). Therefore, interfering with the mitonuclear interactions
within complex I might play a role in disease, in general, and in
T2DM, in particular. In addition to the evidence presented
above, a genetic variant within the nDNA-encoded NDUFB6
subunit of complex I was associated with altered methylation
and gene expression patterns in insulin-resistant individuals
(Ling et al. 2007). Finally, it has been shown that the antidia-
betic agents, the thiazolidinediones, such as metformin, inhibit
respiratory complex I (Brunmair et al. 2004). Hence, elucidat-
ing the structure and function of complex I and the interac-
tions among its subunits are likely to shed light on the
mechanisms underlying mitochondrial involvement in meta-
bolic disorders, in general, and in T2DM, in particular.
Despite many years of efforts, the structure and network of
subunit interactions within mammalian complex I remain only
partially resolved (Vogel et al. 2007), although recent single
particle analysis added much information (Vinothkumar et al.
2014). Although high-resolution crystal structures of complex I
from bacteria (Efremov and Sazanov 2011) and the yeast
Yarrowia lipolitica (Hunte et al. 2010) have shed light on such
interactions, evolutionary distance still leaves the network of
subunit interactions in mammalian complex I unresolved. By
rigorous sequence analysis of nDNA-encoded subunits of
complex I in primates, we identified three subunits (NDUFA1,
NDUFA4, and NDUFC2) that exhibited accelerated amino acid
rate of change, suggesting their candidacy as coevolving with
the fast evolving mtDNA-encoded subunits (Mishmar et al.
2006). Recently, using a combined bioinformatics and molecu-
lar biology approach, we predicted and experimentally verified
the interactions of two complex I nDNA-encoded subunits (i.e.,
NDUFC2 andNDUFA1) with their coevolving mtDNA-encoded
subunit partners (Mishmar et al. 2006; Gershoni et al. 2010).
However, recent evidence has suggested that NDUFA4, the
third subunit exhibiting an accelerated mutation rate, is a
member of OXPHOS complex IV rather than of complex I,
thus excluding this subunit from further analysis of mitonuclear
interactions in the frame of complex I (Balsa et al. 2012).
What might be the physiological importance of mitonu-
clear coevolution in complex I? Remarkably, genetic variants
in close linkage with NDUFC2, a subunit which physically in-
teracts with the mtDNA-encoded complex I subunit ND4,
were recently associated with decreased glucose-stimulated
insulin secretion (Olsson et al. 2011). Furthermore, NDUFC2
was identified as one of five complex I subunits, the expression
levels of which were significantly reduced in insulin-resistant
human skeletal muscle samples (Lefort et al. 2010). Taken
together, these findings led us to hypothesize that mitonu-
clear interactions involving NDUFC2 are important for mito-
chondrial function during evolution and in disease conditions.
Here, we tested our hypothesis by assessing the effect of
NDUFC2 silencing in human cells on mitochondrial function,
cell life, and complex I integrity. Because NDUFC2 underwent
positive selection, we assessed the effect of directed mutagen-
esis of a positively selected amino acid within NDUFC2 on the
interaction with its mtDNA-encoded partner ND4. Finally, we
assessed the association of T2DM with mitonuclear genotype
combinations, including NDUFC2 and mtDNA genetic back-
grounds in Ashkenazi Jews.
Materials and Methods
Cell Line and Cultures
Human D-407 retinal pigment epithelium cells, a kind gift
from R.C. Hunt (Davis et al. 1995), were grown using a
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standard CO2 cell culture incubator in DMEM medium sup-
plemented with 3% fetal calf serum (FCS), 2 mM L-glutamine,
1,000 U/ml penicillin, and 1 mg/ml streptomycin.
Design of siRNA Silencing of NDUFC2 in Human Cells
The siRNA target sequence was designed using the
Dharmacon siDESIGN website (http://www.dharmacon.
com/DesignCenter/DesignCenterPage.aspx, last accessed
September 25, 2014). Specifically, the siRNA oligonucleotide
was designed using the 30 untranslated region sequence of
NDUFC2. The following commercial controls (Dharmacon) for
transient knock-down were used: 1) siRNA agent against
GAPDH (siGAPDH), as a positive control for the silencing pro-
tocol; 2) scrambled siRNA, as a negative control; and 3) Cy3
fluorescently labeled siRNA—siGLO, to assess transformation
efficiency by fluorescence-activated cell sorter (FACS) (see
details below).
Transformation of siRNA into D-407 Cells
About 96 h prior to transformation, frozen cells were thawed
and transferred into a 25-ml flask. Approximately 24 h prior to
transformation, the cells were harvested with trypsin, neutral-
ized by medium, manually counted, and transferred into a
6-well plate (~1.5105 per well) in the presence of 2.5 ml
full growth medium (see Cell Line and Cultures). After 24 h,
0.25 ml of the growth medium was drawn, and the transfor-
mation mixture was prepared as follows: 12 ml TransIT-TKO
transformation reagent (Mirus) was added to 0.25 ml serum-
free DMEM medium (Biological Industries, Bet Ha’emek, Israel)
and mixed by pipetting. siRNA oligonucleotides were added to
a final concentration of 25 nM and the mixture was incubated
at room temperature for 5–20 min. The transformation
medium was slowly added to the wells and incubated for
72 h in a CO2 incubator under standard growth conditions.
Analysis of the siRNA-Treated Cells
siRNA-treated cells were examined 72 h posttransformation
under an inverted phase microscope (Nikon) and photo-
graphed. The cells were then harvested and counted (per
well). siRNA transformation efficiency was evaluated by
FACS, comparing the ratio of cells that were transformed
with Cy3-labled siGLO-labeled siRNA (Dharmacon) with
untreated cells. Specifically, D-407 cells were harvested 14
and 72 h after transformation using trypsin/ethylenediamine-
tetraacetic acid. The samples were analyzed using a
FACSCalibur flow cytometer (Becton Dickinson, San Jose,
CA). The FLH2 filter was used to estimate the red emission
of Cy3. Data were collected and analyzed using CellQuest Pro
4.0.2 analysis software.
Estimating Silencing Efficiency
Total RNA was extracted from untreated or siRNA-treated cells
following the Gentra Versagene total RNA purification kit pro-
tocol. cDNA was produced using a Bio-Rad iScript cDNA
Synthesis kit, according to the manufacturer’s protocol.
cDNA (500 nM, with concentration being determined using
an Eppendorf Biophotometer) was used as template for a
separate real-time polymerase chain reaction (PCR) amplifica-
tion that was performed in a volume of 20ml containing 1
ABsolute Blue SYBR Green ROX Mix (Thermo), with either of
the following primer sets (50 nM of each primer): NDUFC2
primers (forward: 50-GG TTT GCA TCG CCA GCT TC-30;
reverse: 50-CAG GAA AAT CCT CTG GAT G-30) and ß-actin
(forward:50-CGC GAG AAG ATG ACC CAG AT-30; reverse:
50-TCA CCG GAG TCC ATC ACG AT-30). The following PCR
protocol was used in a Stratagene Mx3000P real-time PCR
machine: 15 s at 94 C followed by 40 cycles of denaturation
for 10 s at 98 C, annealing for 20 s at 60 C and extension for
15 s at 72 C. These cycles were followed by a final extension
step of 7 min at 72 C. The threshold cycle (Ct) values were
derived from a standard curve generated with the aforemen-
tioned primers on commercial testis RNA (Ambion). For the
real-time PCR experiment, RNA extracted from nontargeting
siRNA transformed cells (negative control) was used as a cal-
ibrator tissue and ß-actin served as a normalizing gene.
Blue Native Polyacrylamide Gel Electrophoresis Analysis
D-407 cells were treated by NDUFC2 siRNA and a nontarget-
ing control reagent, as described above. Forty-eight hours
posttransformation, the cells were harvested using trypsin
and washed twice with phosphate buffered saline (PBS).
Following removal of residual PBS, the cells were immediately
frozen in liquid nitrogen and kept on dry ice until further anal-
ysis by blue native polyacrylamide gel electrophoresis (BN-
PAGE), performed as described previously (Calvaruso et al.
2008). Lanes were loaded with 80mg of solubilized mitochon-
drial protein. After electrophoresis, the gels were further pro-
cessed for in-gel complex I activity staining or western blotting.
Protein immunodetection was performed using anti-SDHA
(Mito Sciences), anti-NDUFA9, and anti-CORE 2 (Invitrogen)
primary antibodies. Peroxidase-conjugated secondary anti-
mouse or antirabbit IgG antibodies (Invitrogen) were then
used. Antibody binding was detected using ECL plus
(Amersham Biosciences).
Membrane Potential Analysis
D-407 cells were grown in medium containing either 100%
glucose (4.5 g/l) or in medium in which 80% or 90% of the
glucose was replaced by galactose, added as an alternative
carbon source. Forty-eight hours post-siRNA treatment, tetra-
methylrhodamine methyl ester (TMRM) was added to the
wells to a final concentration of 500 nM, as previously
described (Maldonado et al. 2010) and incubated for
30 min followed by PBS washing and cells harvesting. The
cells were then centrifuged, resuspended twice with 200ml
PBS, plated on 96-well plates (Greiner bio-one, white,
655098), and analyzed for TMRM florescence using an
Mitochondrial–Nuclear Coevolution in Complex I GBE
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enzyme-linked immunosorbent assay (ELISA) reader (excita-
tion 488 nm; emission 573 nm).
Site-Directed Mutagenesis at NDUFC2 Amino Acid
Position 46
Human mtDNA-encoded ND4 (previously recoded to the cy-
toplasmic genetic code; Gershoni et al. 2010) and nDNA-
encoded NDUFC2 genes were cloned into the pBD and pAD
plasmids of the yeast two-hybrid assay, as previously de-
scribed. To alter NDUFC2 amino acid position 46, we utilized
our previously cloned pAD–NDUFC2 plasmid (Gershoni et al.
2010) encoding the common leucine variant at amino acid
position 46 as template. For site-directed mutagenesis, we
used the Phusion site-directed mutagenesis protocol
(Finnzyme) with the following primers: 1) NDUFC2 L>V
change: forward: 50-GCCTGATTGATAACGTTATCCGGCGGA
GGCCG-30, reverse: 50-CGGCCTCCGCCGGATAACGTTATCA
ATCAGGC-30; 2) NDUFC2 L>F change: forward: 50-GGCCT
GATTGATAACTTTATCCGGCGGAGGCCG-30, reverse: 50-CG
GCCTCCGCCGGATAAAGTTATCAATCAGGCC-30; and 3)
NDUFC2 V>A change: forward: 50-CTGATTGATAACGCTAT
CCGGCGGAGG-30, reverse: 50-CCTCCGCCGGATAGCGTTAT
CAATCAG-30. The reaction conditions used were according
to manufacturer’s instructions. Briefly, the reaction program
included 18 cycles of annealing at 55 C for 30 s, 9 min ex-
tension at 72 C, followed by Dpn1 treatment in the PCR
buffer used and transformation into the DH5-a Escherichia
coli host strain. The selected colonies were incubated at
37 C for 12 h in 10 ml LB supplemented with 100mg/ml am-
picillin. Plasmid DNA was purified using the Wizard plus SV
minipreps DNA purification system (Promega), according to
the manufacturer’s protocol. The insert was sequenced at
the Ben-Gurion University DNA sequencing facility.
Yeast Two-Hybrid Assay
Yeast two-hybrid analysis was performed using the Yeast
Two-hybrid Phagemid vector kit (Stratagene). The pAD–
NDUFC2-L (wild type, WT) or other pAD–NDUFC2 mutant
plasmids (NDUFC2-V, NDUFC2-A, and NDUFC2-F) were used
as bait, while a plasmid encoding pBD–ND4 was used as prey.
The PJ yeast host strain was cotransformed with plasmids
pAD–NDUFC2 WT (NDUFC2-L) or the mutants and pBD–
ND4 plasmids using the LiAC method. Single transformants
were grown in liquid SC-Leu-Trp to OD600 10, washed twice
with double distilled water (DDW), and diluted to an initial
OD600 of 0.3. For quantitative two-hybrid analysis, the gener-
ation time of the indicated mutants and their respective part-
ner, ND4, were calculated from their growth curves in liquid
SC-Leu-Trp-His media. Cells were grown overnight in SC-Leu-
Trp, washed twice with DDW, diluted 1:10 into 5 ml of pre-
warmed SC-Leu-Trp-His, and OD600 measurements were
taken. Generation times (t) were calculated from the
growth curves according to the equation ODt= OD02t/T.
The generation time calculated for each culture is an average
of at least four independent experiments. Student’s t-test was
performed on the results obtained from at least four indepen-
dent experiments to assess significance.
Western Blot Analysis
In order to assess protein expression of the fused pBD con-
struct, we extracted proteins from yeast, loaded them on a
10% polyacrylamide gel, and analyzed them by western blot
exactly as previously described (Gershoni et al. 2010) utilizing
rabbit polyclonal antibodies raised against the Gal4-binding
domain (Santa Cruz Biotechnology, a generous gift from
Prof. Michal Shapira, BGU). This procedure was applied to
each independent repeat of the yeast two-hybrid assay (four
repeated experiments). Although we attempted to perform
the reciprocal experiment using two commercial antibodies
raised against NDUFC2 (ABCAM and ADAR technology LTD,
respectively), in our hands control extract from cells did not
result in a band with the expected size. In addition, an anti-
body raised against pAD (Santa Cruz Biotechnology, a gener-
ous gift from Prof. Michal Shapira, BGU) did not result in a
clear band. Therefore, we excluded these antibodies from the
current work.
Sequence Alignment and Positive Selection
NDUFC2 cDNA sequences available from GenBank, as well as
the deduced proteins encoded by open reading frames from
39 mammals and 4 nonmammalian vertebrates, were aligned
using ClustalW and T-Coffee. Because both methods resulted
in consistent alignments, we continued using the ClustalW
results for the sake of simplicity. Those species for which
NDUFC2 sequences were available are listed in figure 1. The
cDNA sequence alignment was further utilized for the analysis
of positive selection using SELECTON (selecton.tau.ac.il) (Stern
et al. 2007), as described (Gershoni et al. 2010). Briefly, the
tested hypothesis is whether positive selection is operating on
NDUFC2, as contrasted with a null hypothesis which assumes
that there is no positive selection. The SELECTON server allows
for detecting selective forces even at single amino acid sites.
The ratio of nonsynonymous (i.e., amino acid altering) to syn-
onymous (i.e., silent) substitutions, known as the Ka/Ks ratio, is
used to estimate both positive and purifying selection at each
amino acid site.
The Tested Cohort
DNA samples from individuals of Ashkenazi Jewish origin were
collected by the Israeli Diabetes Research Group. The patient
study group was composed of 1,118 individuals comprising
the following: 1) 719 unrelated T2DM patients (360 men and
359 women; average age 65.8 years) whose DNA samples
were previously analyzed (Feder et al. 2008, 2009) and 2)
399 new individuals described in this study. The 719 patients
were already analyzed for their mtDNA genetic backgrounds
Gershoni et al. GBE
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using restriction fragment length polymorphism (RFLP) sites
throughout the mtDNA sequence, which were reported
along with additional clinical details. Because of DNA sample
limitations, we utilized only a subset of the previously studied
patient cohort. Blood samples from all patients were collected
at seven different medical centers throughout Israel and DNA
was extracted using standard techniques (Puregene; Gentra
Systems, Minneapolis, MN). Similar to the previous (719) pa-
tient group, the new 399 T2DM patients were also family
unrelated. A control cohort comprised two groups: 1) 170
individuals (89 men and 81 women; average age 69.7 years)
who were previously analyzed for their mtDNA genetic
FIG. 1.—Phylogenetic analysis of NDUFC2 at the region encoding amino acid position 46 and flanking sequences. NDUFC2 position 46 is highlighted.
Ape, old world monkeys, prosimians, and nonprimate mammalian sequences are presented on a gray-scale gradient running from light to dark gray,
respectively.
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backgrounds (Feder et al. 2007). All individuals gave written
informed consent prior to sample collection. The study was
approved by the “The Committee on Research Involving
Human Subjects of the Hebrew University-Hadassah Medical
School” (application approval number 36-03.09.04) and by
the local Institutional Review Boards of each participating in-
stitution. 2) An additional group of 189 healthy Ashkenazi
Jews (77 men and 112 women; average age 68.6 years)
were collected at the Albert Einstein College of medicine.
Informed written consent was obtained in accordance with
the policy of the Committee on Clinical Investigation of the
Albert Einstein College of Medicine. In summary, 1,118 unre-
lated T2DM patients and 359 healthy controls were used in
this study (supplementary table S1, Supplementary Material
online).
mtDNA Haplogroup Assignment
Part of the patient samples (N= 719) and from controls
(N= 170) were previously analyzed for mtDNA haplogroup
affiliation using PCR-RFLP of selected mtDNA markers (Feder
et al. 2007, 2008, 2009). Genotype information for the 420
patients added in this study was obtained using the
MetaboChip single nucleotide polymorphism (SNP) chip
which harbors 194,263 nDNA SNPs and 126 mtDNA SNPs
(http://www.illumina.com/, last accessed September 25,
2014). These mtDNA SNPs were utilized for detailed mtDNA
haplogroup assignment using HaploGrep (Kloss-Brandsta¨tter
et al. 2011). Three hundred and ninety-nine patients (204 men
and 195 women; average age 62.8 years) of the initial 420
patients had sufficient SNP information to allow assignment to
one of the four haplogroup clusters (HV, UK, IW, and JT). The
control group (N= 359) was analyzed for their mtDNA hap-
logroup affiliation as follows: 170 healthy controls were pre-
viously analyzed for their mtDNA haplogroup affiliation (Feder
et al. 2007). The additional healthy controls (N= 189) were
genotyped using the Affymetrix 6.0 SNP chip (http://www.
affymetrix.com, last accessed September 25, 2014). The
chip used harbored 906,481 nDNA SNPs and 119 mtDNA
SNPs, of which 28 were informative in our analyzed popula-
tion for mtDNA haplogroup assignment in HaploGrep (sup-
plementary table S2, Supplementary Material online) (Kloss-
Brandsta¨tter et al. 2011). Haplogroup distribution in all pa-
tients and controls is reported in table 1.
Amplifying and Sequencing the Coding Region of
NDUFC2
PCR exon amplification ofNDUFC2was performed using DNA
samples as templates and forward and reverse primers en-
compassing the sequence of each exon (supplementary
table S3, Supplementary Material online). To identify
common variants (present at a frequency >1%) within our
studied populations, NDUFC2 exons were PCR amplified. For
PCR amplification during the genotyping process, we used 50
ng of DNA from each sample (collected from 25 randomly
chosen, healthy Ashkenazi Jews) as template in a standard
20ml PCR assay containing 250 nM dNTPs (Bio-Lab,
Jerusalem, Israel), 10 nM of each primers (IDT, Jerusalem,
Israel), 1 U of Taq-polymerase (Bio-Lab), varying concentration
of MgCl2 (supplementary table S4, Supplementary Material
online), and 10 Taq Polymerase (TAQ) reaction buffer (Bio-
Lab). The PCR program included a denaturation stage of 4 min
(94C) followed by 30 cycles of denaturation at 94 C, anneal-
ing for 30 or 60 s at different temperatures according to the
calculated temperature of melting (TM) of the primers em-
ployed (supplementary table S4, Supplementary Material
online), extension at 72 C, a final extension of 5 min at
72 C, and a concluding step in which the reactions were
cooled to 10 C. The products were visualized on a 1.5%
agarose gel stained with ethidium bromide and stored at
20 C until use. The specific conditions for each reaction
are summarized in supplementary table S4, Supplementary
Material online. After amplification, the samples were cleaned
with a DNA purification kit (Promega) and sequenced by the
Applied Biosystems (ABI) PRISM 3100 Genetic Analyzer at the
Ben Gurion University DNA sequencing core facility.
Polymerase Chain Reaction Restriction Fragment Length
Polymorphism
A common amino acid replacement variant was identified in
exon 1 of NDUFC2 (rs8875) in our tested population
(Ashkenazi Jews). To screen for the allele distribution of this
variant in our studied populations, a 326-bp NDUFC2 exon 1
segment was PCR amplified using forward (50-CTT ACG GTT
TCT GCC GGA TG-30) and reverse (50-TGA CAC TCT GGC
TCT GCT TG-30) primers. For restriction digestion of the am-
plified sequence, the enzyme HpyCH4IV, which recognizes
the ACGT/TGCA motif, was used. Each digestion reaction
(total volume of 20ml) contained 2ml buffer, 0.5ml enzyme,
12.5ml DDW, and 5ml PCR product. Digestion was performed
at 65 C for 1 h. As the enzyme does not recognize the
common C variant but rather the rare G variant, the restriction
Table 1
Mitochondrial DNA Haplogroup Distribution in Patient and Control
Groups
mtDNA Haplogroup
Cluster
Patient Control Proportion
of Patients
HV 394 (35.2%) 145 (40.4%) 0.731
UK 431 (38.6%) 128 (35.7%) 0.771
JT 163 (14.6%) 43 (12%) 0.791
IW 130 (11.6%) 43 (12%) 0.751
Total 1,118 359 0.757
NOTE.—The actual number of individuals is listed, while the percentages of
each haplogroup cluster in each of the studied groups are presented in parenthe-
ses. The proportion of patients in each haplogroup cluster is also listed.
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digest was expected to yield 215 and 111 bp bands. This assay
was applied to the entire patient and control cohorts.
Statistical Analysis
We first used an RC (rows columns) test of independence
to compare the distribution of the four mtDNA genetic back-
grounds (i.e., haplogroup clusters HV, UK, JT, and IW) and
three nDNA NDUFC2 genotypes (i.e., CC, CG, and GG)
among our T2DM patients and controls. Next, to detect can-
didate mtDNA–nDNA genotype combinations differing in
their representation between the patients and controls, we
used a permutation test. Specifically, we divided the tested
samples into 12 different mtDNA–nDNA genotypes (4 mtDNA
lineages3 nDNA NDUFC2 genotypes = 12 mtDNA–nDNA
genotypes; table 2). The diabetic status (a binary indicator
variable, with 0 representing healthy individuals and 1 repre-
senting T2DM patients) was randomly shuffled among all
samples. Then, the proportion of T2DM samples in each of
the mtDNA–nDNA genotypes was calculated, and the abso-
lute difference (two-tailed test) between each of these values
and the general tendency to develop the disease in the entire
population was recorded. This procedure was repeated
10,000 times. P values were estimated as the proportion of
cases in which the absolute difference obtained during the
simulation was equal to or greater than that of the original
data set. The test was performed using MATLAB script. Finally,
we used logistic regressions to assess whether the susceptibil-
ity of developing T2DM (represented by a binary indicator
variable taking on values 0 and 1) differed among mtDNA–
nDNA genotypes, while adjusting for individual characteristics,
including gender and age. By converting the categorical var-
iable “mtDNA–nDNA genotype” into binary numbers, we
compared the candidate mtDNA–nDNA genotype detected
using the permutation test (i.e., HV–CC) with each of the
other 11 mtDNA–nDNA genotypes using a single test.
Because this variable is composed of 12 classes, its inclusion
in a logistic regression model requires generating 11 indicator
variables. The coefficients of these indicator variables indicate
whether the propensity to develop T2DM in each of the re-
spective mtDNA–nDNA genotypes differs from that of the
reference genotype (i.e., HV–CC). To obtain an estimate of
the relative risk of individuals belonging to a particular
mtDNA–nDNA genotype to develop T2DM, odds ratios
(ORs) were calculated. To correct for multiple testing in the
logistic regression and the permutation test, we estimated q
values. Specifically, q values (measuring the minimum false
discovery rate, which is incurred when calling a test significant)
were estimated using the smoother method proposed by
Storey and Tibshirani (2003) and the bootstrap method pro-
posed by Storey (2002) and Storey et al. (2004), both im-
planted in the QVALUE software package. Student’s t-test
was used to estimate differences between mitochondrial
membrane potential measurements or cell counts in
NDUFC2-silenced versus untreated cells, taking into account
repeated measurements collected from independently re-
peated experiments (see Results).
Web Resource
1. SELECTON server: http://selecton.tau.ac.il/
2. Predictprotein server: http://www.predictprotein.org/
3. Dharmacon siDESIGN website: http://www.dharmacon.
com/DesignCenter/DesignCenterPage.aspx
4. HAPMAP server: www.hapmap.org
Table 2
The Results of Permutation Tests Searching for Candidate mtDNA–nDNA Genotypes that Differ in Their Representation between Patients and
Controls
mtDNA haplogroup–NDUFC2
genotype combination
Diabetic Total
Number
Diabetic
Proportion
P value q Value (n0=0.227)
Smoother
q Value (n0=0.208)
Bootstrap
HV_CC 183 265 0.691 0.006 0.016 0.015
HV_CG 184 236 0.780 0.413 0.128 0.117
HV_GG 27 38 0.711 0.557 0.138 0.127
IW_CC 67 82 0.817 0.230 0.105 0.096
IW_CG 54 81 0.667 0.063 0.057 0.052
IW_GG 9 10 0.900 0.469 0.128 0.117
JT_CC 94 118 0.797 0.318 0.124 0.114
JT_CG 52 68 0.765 0.887 0.202 0.185
JT_GG 17 20 0.850 0.439 0.128 0.117
UK_CC 206 284 0.725 0.200 0.105 0.096
UK_CG 174 214 0.813 0.036 0.049 0.045
UK_GG 51 61 0.836 0.172 0.105 0.096
Total 1,118 1,477 0.757
NOTE.—First column, left: The ﬁrst two letters correspond to the mtDNA haplogroup cluster and the last two letters represent the NDUFC2 genotype (in nucleotides).
Numbers in the second and third columns are the actual numbers of samples. q values (measuring the minimum false discovery rate, which is incurred when calling a test
signiﬁcant) were estimated using the smoother method proposed in Storey and Tibshirani (2003) and the bootstrap method proposed in Storey (2002), both implanted in the
QVALUE software package (Storey 2002). p0 measures the overall proportion of true null hypotheses.
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5. dbSNP server: www.ncbi.nlm.nih.gov/SNP (All URLs were
accessed on September 25, 2014.)
Results
Assessing the Functional Role of NDUFC2 in Cells
We previously showed that NDUFC2, and the mtDNA-
encoded complex I subunit ND4, coevolved during primate
evolution and interact physically. This interaction gained
recent support from single particle analysis of mammalian
complex I (Vinothkumar et al. 2014). Hence, we assessed
the importance ofNDUFC2 for mitochondrial function, in gen-
eral, and complex I activity, in particular. To assess the role
played by NDUFC2 in cell life and mitochondrial function, we
employed siRNA to silence the expression of NDUFC2.
Oligunucleotide transformation into human D-407 cells re-
sulted in ~90% reduction in NDUFC2 transcript levels in
siRNA-treated cells, as compared with cells treated by a
nontargeting silencing agent (supplementary fig. S1,
Supplementary Material online). Cell counting (performed in
four independent experiments) 72 h posttreatment revealed
significant reduction in the amount of NDUFC2-silenced cells,
as compared with cells challenged with a nontargeting
silencing agent in the D-407 cell line (t-test, P= 0.003)
(supplementary fig. S2, Supplementary Material online).
Similar results were obtained using HEK293 cells (data not
shown). Hence, NDUFC2 silencing reduced the growth rate
of human cells.
NDUFC2 Is Important for OXPHOS Function
To determine the importance ofNDUFC2 for OXPHOS activity,
in general, and for OXPHOS complex I, in particular, we first
measured mitochondrial membrane potential in D-407 cells
by assessing the absorption of the tetramethylrhodamine
methylester (TMRM), as previously described (Ehrenberg
et al. 1988; Lemasters and Ramshesh 2007; Maldonado
et al. 2010), 48 h after NDUFC2 siRNA silencing. This analysis
revealed a significant 15% reduction in the fluorescent signal
within the siRNA-treated cells, relative to the nontargeting
knock-down controls (three independent experiments, two-
tailed t-test, P<0.001). Because the use of galactose as a
major carbon source in cell culture media is an established
condition to drive cells into dependence on OXPHOS as a
major source for ATP production (Reitzer et al. 1979;
Bayona-Bafaluy et al. 2011), we grew NDUFC2-silenced cells
and control cells either in full medium (i.e., with glucose as a
carbon source) or in medium in which 80% or 90% of the
glucose was replaced by galactose (i.e., 20% or 10% glucose-
containing medium, respectively; see Materials and methods).
Mitochondrial membrane potential (as assessed by TMRM
measurements) was reduced by 30% in the NDUFC2-silenced
cells, as compared with cells treated by nontargeting siRNA or
control cells grown in galactose-based media (two-tailed
t-test, P< 0.001) (fig. 2). These results indicate that NDUFC2
is important for mitochondrial function.
NDUFC2 Silencing Affects Complex I Stability
Because we recently underlined the importance of NDUFC2
for mitonuclear protein–protein interactions (Gershoni et al.
2010), we asked whether the function of NDUFC2 is impor-
tant for complex I assembly and stability. To this end, we used
BN-PAGE to examine proteins extracted from D-407 cells that
were treated either by NDUFC2 siRNA or by nontargeting
control siRNA. A notable decrease in the total amount of as-
sembled complex I was observed in theNDUFC2 siRNA treated
cells. This is consistent with decreased NADH oxidation, which
is mediated primarily by complex I, as measured by an in-gel
activity stain assay using the artificial electron acceptor nitro-
tetrazolium blue in the siRNA-treated cells. The mobility of
bands corresponding to complex I observed in all assays was
identical in the control and siRNA-treated cells, indicating that
the residual amount of complex I in the siRNA-treated cells
likely corresponds to the fully assembled protein complex. We
FIG. 2.—Relative quantification of mitochondrial membrane potential
in the D-407 cell line 48 h after NDUFC2 siRNA treatment. D-407 cells
either treated byNDUFC2-silencing siRNA agent (blue columns) or by non-
targeting siRNA agent (red columns) were grown either in full medium
(4.5 g/l glucose) or in medium in which 80% or 90% of the glucose was
replaced by galactose (i.e., 20% or 10% glucose-containing medium, re-
spectively). Cells were incubated with 500-nM TMRM, an indicator of
mitochondrial membrane potential, and fluorescence levels were mea-
sured by ELISA (see Materials and methods). X axis: In each of the exper-
iments, column pairs are presented—a red column for the membrane
potential measurements in nontargeting siRNA-treated cells and a blue
column for the measurements in NDUFC2 siRNA-treated cells. Three ex-
periments are presented, differing in the cell growth media (all DMEM
based): Full medium, 4.5g/l glucose; 20% glucose, 0.9 g/l glucose, 3.6g/l
galactose; 10% glucose, 0.45 g/l glucose, 4.05 g/l galactose. Y axis:
Membrane potential represented in arbitrary units (1–100). In each of
the experiments, measurements obtained in cells treated with the nontar-
geting agent are considered as the maximum value (100 arbitrary units).
**P< 0.001, two-tailed t-test.
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did not observe any subassembly intermediates representing
degraded or partially assembled complex I in the siRNA-trea-
ted cells. These data suggest that NDUFC2 indeed plays a role
in the integrity (i.e., assembly and/or stability) of complex I
(fig. 3 and supplementary fig. S3, Supplementary Material
online).
NDUFC2 Amino Acid Position 46 Is Important for
Mitonuclear Protein–Protein Interactions
As the first step toward identifying amino acid positions that
are important for protein–protein interaction of NDUFC2 with
its mtDNA-encoded partner and their possible involvement in
human health, we performed in silico sequence analysis. This
analysis predicted that amino acid positions 41–46 likely con-
stitute a protein–protein interaction domain (fig. 4). Within
this putative domain, one amino acid (D44) was strongly neg-
atively selected, whereas two others (I43 and L46) were pos-
itively selected during primate evolution (Gershoni et al.
2010), thus suggesting their functional potential. Only one
of these amino acids, L46, also harbored a common human
genetic variant (L46V, dbSNP accession number rs8875) which
attracted our attention to its possible association with human
genetic phenotypes (see below). Therefore, we focused our
further analyses on the functional role of NDUFC2 amino acid
position 46.
We anticipated that changes at a single amino acid position
might only quantitatively alter the protein-binding capacity of
NDUFC2. Previously, the yeast two-hybrid assay was adapted
to measure yeast growth rate in selective liquid media, thus
assessing affinity changes in protein–protein interactions in a
semiquantitative manner (Fridman et al. 2010). To employ this
same approach for our purposes, we cloned the mtDNA-
encoded ND4 gene, recoded to comply with the cytoplasmic
genetic code, into a pBD plasmid, as previously described
(Gershoni et al. 2010). To assess the importance of NDUFC2
position 46 for the interaction with ND4, we cotransformed
the pBD–ND4 construct into yeast along with each of four
differentNDUFC2–pAD constructs (A–D), encoding a different
amino acid at position 46. The replacements within position
46 were planned to represent amino acid changes during
mammalian evolution and human population genetic variants
while retaining hydrophobicity. These included the following:
1) NDUFC2-L, encoding leucine at position 46, representing
the first human allele; 2) NDUFC2-V, encoding valine at posi-
tion 46, corresponding to the second human allele; 3)
NDUFC2-A, encoding alanine at position 46, a small hydro-
phobic amino acid, representing the most abundant amino
acid in nonprimate mammals (fig. 1); and 4) NDUFC2-F,
encoding phenylalanine at position 46, a large hydrophobic
amino acid, representing the most abundant amino acid in old
world monkeys (fig. 1). Yeast growth rates, calculated from
the growth curves of each experiment, demonstrated a sig-
nificant ~40% decrease in NDUFC2-F/ND4 affinity, as com-
pared with that of NDUFC2-L/ND4 affinity (fig. 5a, t-test,
P<0.001). In contrast, a slight but significance increase in
the NDUFC2-A/ND4 growth rate was observed, as compared
with that of NDUFC2-L/ND4 growth rate (fig. 5a, t-test,
P= 0.02). In order to assess whether the observed differences
in protein–protein interaction is true or due to a lack of protein
expression, we performed western blot analysis (fig. 5b). Close
inspection revealed a possible difference in band intensities.
Because each of the yeast growth rate experiments (fig. 5a)
were repeated four times and each was accompanied by a
western blot analysis (see Materials and Methods), we in-
spected these other blots. We found that the apparent
band intensities’ differences did not correlate with the ob-
served consistent differences in growth rates of the tested
clones (fig. 5a). Because equal amounts of proteins were
loaded onto the lanes in all western blots, we interpret the
band intensities’ differences as reflecting technical variation
among the blots, rather than true differences in protein ex-
pression levels. Hence, this analysis confirmed that the pBD
construct was indeed expressed in the presence of all the
tested proteins and mutants while growing the yeast
in -L-W restrictive media, and, therefore, the observed differ-
ences in interaction levels are likely real. Taken together, these
results support a functional role for NDUFC2 position 46 in
mitonuclear protein–protein interactions. However, in our
hands, no significant differences were observed while com-
paring the growth curves of yeast harboring ND4/NDUFC2-V
or ND4/NDUFC2-L (fig. 5a). We, therefore, hypothesized that
if the human genetic variants L46V affect mitonuclear
FIG. 3.—NDUFC2 is required for complex I integrity. A representative
experiment showing the analysis of total protein extracts by BN-PAGE.
Con—protein extract from cells treated with a nontargeting siRNA control
oligonucleotide; siC2—protein extract from cells treated with an NDUFC2
siRNA oligonucleotide. Complex I in-gel activity staining assay and immune
detection of complex I (NDUFA9), complex III (core II), and control CII
70kDa were performed in protein extracts from control cells treated
with nontargeting siRNA (left lane) or NDUFC2-targeting siRNA (right
lane). A notable decrease in the amount of fully assembled complex I
was identified, as was a decrease in complex I activity. CII—OXPHOS com-
plex II.
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interactions, such an effect should be subtle, below the sen-
sitivity of our test, as well as many other available tests. To
increase the sensitivity and overcome this obstacle, we ex-
plored an approach with higher sensitivity. To this end, we
designed a disease-association study.
NDUFC2 Amino Acid Position 46 Is the Only Position
Harboring a Common Nonsynonymous Variant in
Caucasians, in General, and Ashkenazi Jews, in Particular
Because amino acid position 46 proved important for NDUFC2
protein interaction with its mtDNA-encoded partner ND4, we
hypothesized that natural genetic variants in this site should
have phenotypic consequences. A screen of publicly available
databases for nonsynonymous polymorphisms in NDUFC2
(HAPMAP, www.hapmap.org [last accessed September 25,
2014]; dbSNP, www.ncbi.nlm.nih.gov/SNP [last accessed
September 25, 2014]) revealed only a single validated nonsyn-
onymous common variant—the one encoding amino acid po-
sition 46 (rs8875). This SNP yielded an L46V substitution, in
which the leucine allele encompassed ~70% and the valine
allele comprised ~30% of Caucasian genetic diversity.
Because a linked SNP to NDUFC2 altered the susceptibility to
glucose-stimulated insulin secretion (Olsson et al. 2011), a di-
abetes-related phenotype, we asked whether the NDUFC2
L46V SNP could alter susceptibility to diabetes. Because the
T2DM patient cohort available to us was of Ashkenazi Jewish
origin, and because bottlenecks could, in principle, alter the
prevalence of rare variants in this population, we initially
screened for the most common variants by sequencing all
the coding NDUFC2 exons in 25 healthy subjects. This
screen confirmed the existence of the above-mentioned
NDUFC2 nonsynonymous variant, rs8875, and did not reveal
any other amino acid replacements. As position 46 directly
affected the interaction of NDUFC2 protein with its mtDNA-
encoded partner ND4, we aimed toward assessing the asso-
ciation of genotype combinations involving this SNP and
mtDNA SNPs with T2DM.
A Mitonuclear Genotype Combination Involving NDUFC2
Position 46 Alters Susceptibility to Developing T2DM
We investigated the association of combinations of the
NDUFC2 amino acid replacement SNP rs8875 and mtDNA
genetic backgrounds (haplogroups) with T2DM in patient
and control cohorts of Ashkenazi Jewish origin. First, using
PCR-RFLP, we assessed the allelic composition of the L46V
NDUFC2 variant in our cohort of 1,118 patients and 359
healthy controls. This screen revealed a similar allelic compo-
sition as seen in the general non-Jewish Caucasian population,
that is, G (leucine allele):C (valine allele) was 0.74:0.26 in the
controls and 0.7:0.3 in patients. In addition, we could not
detect any significant differences in the distribution of the
respective genotypes (i.e., CC, CG, and GG) among the pa-
tients and controls (RC test of independence; G= 4.868,
degrees of freedom [DF] = 2, P= 0.088).
Second, we assessed the association of mtDNA hap-
logroups with T2DM. To avoid sample size issues while com-
paring frequencies of mtDNA haplogroups, we grouped the
mtDNA haplogroups according to phylogenetic consider-
ations. This resulted in four merged haplogroup clusters: HV
(haplogroups H and V), UK (haplogroups U and K), JT (hap-
logroups J and T), and IW (haplogroups I, W, X, and N1). The
distribution of these four mtDNA haplogroup clusters was
consistent between the patient and control cohorts (RC
test of independence; G= 3.933, DF = 3, P= 0.269; table 1).
This finding is consistent with the previously observed lack of
association of mtDNA haplogroups as a sole genetic compo-
nent with T2DM in Caucasians (Saxena et al. 2006).
To detect candidate mtDNA–nDNA genotype combina-
tions differing in their representation between the patients
and controls, we divided the tested samples into 12 different
mtDNA–nDNA genotypes (4 mtDNA lineages3 nDNA
NDUFC2 genotypes = 12 mtDNA–nDNA genotypes; table 2).
Using a permutation test, we found that the HV–CC genotype
(i.e., mtDNA haplogroup HV and the NDUFC2 SNP genotype
CC) was underrepresented in the patient group (P= 0.006 and
q= 0.016; table 2). Therefore, this genotype combination
(HV–CC) was used as the reference group in the logistic re-
gression analysis designed to test whether susceptibility to
developing T2DM differed among the mtDNA–nDNA geno-
types. By converting the categorical variable mtDNA–nDNA
genotype into a set of binary predictor variables (i.e.,
dummy variable), we could compare the reference mtDNA–
nDNA genotype, detected using the permutation test (i.e.,
HV–CC) with each of the other 11 mtDNA–nDNA genotypes
using a single test, while controlling for possible effects of
FIG. 4.—Graphic summary of NDUFC2 domain predictions. Red background, N-myristylation site and protein–protein interaction motif (http://www.
predictprotein.org/); gray background, transmembrane domain; turquoise background, tyrosine kinase phosphorylation; green background, casein kinase II
phosphorylation site. Arrow points to amino acid position 46.
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other individual characteristics (e.g., sex and age) (table 3). Our
analysis revealed that the HV–CC genotype was significantly
underrepresented in T2DM patients, particularly in compari-
son with five mtDNA–nDNA genotypes, HV–CG, UK–CG,
UK–GG, IW–CC, and JT–CC (P= 0.029, OR = 1.58;
P= 0.002, OR = 2.01; P= 0.018, OR = 2.44; P= 0.033,
OR = 1.98; P= 0.018, OR = 1.90, respectively, table 3). These
results also remained significant after correction for multiple
testing (q= 0.020, q= 0.006, q= 0.018, q= 0.020, q= 0.018,
respectively). This implies that the HV–CC mitonuclear geno-
type likely confers a protective effect against T2DM, especially
relative to certain mitonuclear genotype combinations.
FIG. 5.—NDUFC2 amino acid position 46 is important for mitonuclear protein–protein interactions in a yeast two-hybrid assay. (a) Yeast growth rates,
reflecting the levels of interaction of NDUFC2 with ND4. Yeast cells were transformed with the ND4–pBD construct in combination with either of the
following constructs: NDUFC2-L (leucine), NDUFC2-V (valine), NDUFC2-F (phenylalanine), or NDUFC2-A (alanine). NEG-AD, negative control (plasmid ND4–
pBD cotransformed with an empty pAD, NEG-AD). NEG-BD, negative control (plasmidNDUFC2–pAD cotransformed with an empty or pBD vector, NEG-BD).
For assessing fold change in NDUFC2–ND4 interaction affinities, measurements of the generation rate of the yeast two-hybrid assay strains grown in selective
liquid media lacking histidine were compared with cells expressing NDUFC2-L (see Materials and Methods). Significance is estimated relative to cells
expressing wt NDUFC2-L. Fold increases or decreases in NDUFC2–ND4 interaction affinities were measured as the generation time of the different yeast
two-hybrid strains grown in liquid selective media lacking histidine (Fridman et al. 2010). Significance—all measurements were compared with NDUFC2-L.
*P= 0.02; **P< 0.001; NS, nonsignificant. (b) Western blot analysis of pBD expression. Gel loaded with protein extract from yeast transfected with (from left
to right): 1) NDUFC2-L/empty pBD; 2) NDUFC2-A/ND4–pBD; 3) NDUFC2-F/ND4–pBD; 4) NDUFC2-V/ND4–pBD; 5) NDUFC2-L/ND4–pBD.
Mitochondrial–Nuclear Coevolution in Complex I GBE
Genome Biol. Evol. 6(10):2665–2680. doi:10.1093/gbe/evu208 Advance Access publication September 22, 2014 2675
 at :: on O
ctober 19, 2015
http://gbe.oxfordjournals.org/
D
ow
nloaded from
 
Discussion
In this work, we provided support for our hypothesis that
mitonuclear interactions and coevolution are important for
cell life. We focused our analyses on NDUFC2, an nDNA-
encoded complex I subunit that directly interacts and
coevolves with mtDNA-encoded subunits. We found that
downregulation of NDUFC2 in human cells decreased mito-
chondrial membrane potential, especially in growth conditions
that prefer use of OXPHOS, and affected the integrity of com-
plex I. Moreover, site-directed mutagenesis in the positively
selected amino acid 46 of NDUFC2 significantly affected the
direct interaction of NDUFC2 with the mtDNA-encoded ND4
subunit. Finally, we found that certain genotype combinations
of human variants within amino acid 46 in NDUFC2 and the
mitochondrial genome affected the susceptibility to develop
T2DM. Overall, these combined pieces of evidence offer
further support for the role of NDUFC2 in complex I
protein–protein interactions, in general, and to mitonuclear
interactions, in particular, and suggest that NDUFC2 is likely
involved in the structural stability of complex I. These findings
also lend insight into the importance of mitonuclear interac-
tions for the stability and function of complex I.
Being one of the accessory subunits of complex I, that is, a
component that was added to complex I during the course of
evolution yet was not present in the bacterial ancestor, the
functionality of NDUFC2 has not been well studied to date.
The overall functional analysis of NDUFC2 revealed a notable
decrease in the total amount of assembled complex I, which
was consistent with the decreased NADH oxidation and with
the significant reduction in the mitochondrial membrane po-
tential in cells. Thus our approach demonstrates the
importance of this subunit for the structural integrity of mam-
malian complex I and for mitonuclear interactions within the
complex. Hence, our study paves the path toward investigat-
ing the functional importance of other accessory subunits of
the complex, as well as their importance for the network of
subunit interactions in complex I. Because complex I is the
protein complex most involved in mitochondrial disorders,
being vital in complex disorders, such as Parkinson’s disease
(Winklhofer and Haass 2010) and oncocytomas (Zimmermann
et al. 2011), deciphering the functionality of the 44 subunits of
the complex and their network of interaction is of fundamen-
tal importance for understanding the molecular basis of com-
plex I involvement in these disorders.
Our site-directed mutagenesis experiments indicate that
the positively selected amino acid 46 in NDUFC2 is essential
for its interaction with the mtDNA-encoded ND4 subunit. A
phylogenetic analysis of NDUFC2 revealed that amino acid
position 46 was mainly occupied by the following three hy-
drophobic amino acid residues (fig. 1): 1) alanine, which is
present in the majority of the nonprimate mammals and pro-
simians; 2) phenylalanine, which became fixed in old world
monkeys; and 3) leucine, which became fixed during the ra-
diation of apes. Notably, the less prevalent human genetic
variant of amino acid 46, replacing a leucine for a valine, ap-
parently occurred only once during mammalian evolution.
Thus, all the amino acid replacements that we performed at
NDUFC2 position 46 were previously chosen during evolution
and were successfully retained in living organisms. Because
“swapping” of this amino acid alone led to an altered ability
of human NDUFC2 to interact with its mtDNA-encoded bind-
ing partner (ND4), it is likely that in order to maintain complex I
integrity during evolution, additional compensatory changes
Table 3
Logistic Regression Comparing the Propensity to Develop T2DM between Individuals Pertaining to the HV–CC genotype and Those in Each of the
Other 11 mtDNA–nDNA genotypes
Variable Coefﬁcient (SE) Odds Ratio (95% CI) P Value q Value (n0=0.275)
Smoother
q Value (n0=0.260)
Bootstrap
Constant 3.63 (0.449) 0.000
HV_CG 0.46 (0.21) 1.58 (2.38–1.05) 0.029 0.020 0.019
HV_GG 0.14 (0.389) 1.15 (2.47–0.54) 0.718 0.197 0.186
UK_CC 0.23 (0.192) 1.25 (1.83–0.86) 0.243 0.088 0.083
UK_CG 0.70 (0.224) 2.01 (3.12–1.3) 0.002 0.006 0.006
UK_GG 0.89 (0.377) 2.44 (5.11–1.17) 0.018 0.018 0.017
IW_CC 0.68 (0.32) 1.98 (3.7–1.06) 0.033 0.020 0.019
IW_CG 0.15 (0.277) 0.86 (1.48–0.5) 0.585 0.177 0.167
IW_GG 1.54 (1.07) 4.65 (37.86–0.57) 0.151 0.065 0.062
JT_CC 0.64 (0.27) 1.90 (3.22–1.12) 0.018 0.018 0.017
JT_CG 0.36 (0.321) 1.44 (2.69–0.77) 0.261 0.088 0.083
JT_GG 1.10 (0.651) 3.01 (10.77–0.84) 0.091 0.046 0.043
NOTE.—Variable: Model constant and the compared mtDNA–nDNA genotypes. The test compares each of the genotypes with the reference genotype (HV–CC).
Coefﬁcient (standard error, 1 SE) and odds ratio (95% conﬁdence intervals, CI) are listed. P values (measuring the minimum false-positive rate, which is incurred when
calling a test signiﬁcant) and q values (measuring the minimum false discovery rate, which is incurred when calling a test signiﬁcant) were estimated using the smoother
method proposed in Storey and Tibshirani (2003) and the bootstrap method proposed in Storey (2002), both implanted in the QVALUE software package (Storey et al. 2004).
p0 measures the overall proportion of true null hypotheses. Bold and underlined—signiﬁcant.
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must have occurred and were selected for. This possibility is
currently under investigation.
How could one explain the effect of amino acid replace-
ment at NDUFC2 position 46 on the binding capacity of the
protein? Because the amino acids that we encoded into the
NDUFC2 constructs (i.e., A, F, V, and L) are similar in their
hydrophobic properties, the simplest explanation for the af-
finity differences would be the effect of amino acid size.
Indeed, this interpretation is supported by our experiments.
While introducing the largest amino acid (phenylalanine) led
to decreased protein–protein interactions, the smallest amino
acid tested (alanine) led to slightly increased, yet significant,
levels of protein–protein interactions.
Although we showed the importance of mitonuclear
coevolution and physical interactions involving NDUFC2 for
the structural integrity of complex I, it was unclear how such
interaction affects the phenotype of the organism. In order to
evaluate this point, we took a step toward assessing the im-
portance of mitonuclear interactions for human health. Here,
we showed that a common genetic variant within NDUFC2
altered the susceptibility of developing T2DM only in combi-
nation with a certain mtDNA genetic background (haplogroup
cluster HV). This implies that both the nDNA and the mtDNA-
encoded variants in this genotype combination should have
functional attributes. The first support for this hypothesis
came when we assessed the functionality of one participant
of the T2DM-associated mitonuclear combination, the
common NDUFC2 L46V variant. Sequence analysis using
SELECTON revealed that amino acid position 46 in NDUFC2
underwent positive selection during mammalian evolution,
thus reflecting functional potential. Second, we performed a
domain analysis of NDUFC2 and showed that this amino acid
position is predicted to be involved in protein–protein interac-
tions. Third, we showed that siRNA-mediated knock-down of
NDUFC2 affected complex I integrity. Fourth, using a modified
yeast two-hybrid assay to reflect quantitative differences in
protein–protein interactions while mutating amino acid 46,
we determined the contribution of NDUFC2 position 46 to
mitonuclear protein–protein interactions. Finally, the mtDNA
haplogroup cluster HV was previously associated with altered
risk to develop neurological disorders, including schizophrenia
(Amar et al. 2007) and Parkinson’s disease (Hudson et al.
2013), and had a modest protective effect against AIDS pro-
gression (Guzma´n-Fulgencio et al. 2013). Thus, both NDUFC2
amino acid 46 and mtDNA haplogroup cluster HV indeed
have functional implications. Nevertheless, in our hands, no
clear functional difference was observed between the valine
and leucine nonsynonymous variants occupying NDUFC2
amino acid position 46 in humans. Because more radical
amino acid substitutions that we performed revealed that
NDUFC2 amino acid position 46 is functionally important, it
is plausible that the leucine to valine nonsynonymous change
has a more subtle effect. To assess such subtle impact, we
performed a disease association study, a well-known
approach designed to identify marginal phenotypic impacts
of genetic variants. This study focused on T2DM, because
mounting evidence supports the genetic involvement of
OXPHOS in the etiology of T2DM.
Several studies have pointed out T2DM association of
genetic variants both in nDNA-encoded mitochondrial genes
(Krempler et al. 2002; Muller et al. 2003; Lindholm et al. 2004;
Wang et al. 2004) and in mtDNA (Poulton et al. 2002; Guo
et al. 2005; Mohlke et al. 2005; Fuku et al. 2007; Nishigaki
et al. 2007; Feder et al. 2009; Achilli et al. 2011). However,
many of these studies assessed the disease association of var-
iants either within the nDNA or in the mtDNA, thus overlook-
ing the impact of mitonuclear interactions. We previously
showed that T2DM association with mtDNA genetic back-
grounds varied among populations and depended on the
health status of the parents (Feder et al. 2009), suggesting
the involvement of nDNA-encoded modifying factors in the
phenotypic effect of mtDNA genetic variants. Other studies
indicated that the penetrance of mtDNA pathologic mutations
is modulated by the nDNA genetic background (Hudson et al.
2005; Potluri et al. 2009) and vice versa (Gaweda-Walerych
et al. 2010). Hence, the very basic and unique characteristics
of the mitochondrial genetic system, namely, its interplay with
mtDNA-encoded, nDNA-encoded, and environmental factors
should be considered while investigating mitochondrial ge-
netic involvement in T2DM, and probably in other complex
phenotypes (Zhu et al. 2014). In this study, we demonstrated
one aspect of this interplay, namely that association of mito-
chondrial genetic factors with T2DM in Caucasians occurred
only when a specific mtDNA genetic background (HV) was
combined with a specific NDUFC2 nonsynonymous variant.
We interpreted these results to mean that the mitonuclear
genotype combination HV–CC is likely involved in the etiology
of T2DM, at least in Ashkenazi Jews. This finding has a
broader implication: Most successful genome-wide associa-
tion studies reveal only the marginal phenotypic effect of cer-
tain genetic factors. These studies have limited statistical
capacity and frequently encounter type 1 errors for the detec-
tion of contributing epistatic interactions to complex disorders
(Ueki and Cordell 2012). Our study demonstrated the advan-
tage of the candidate gene approach while searching for
T2DM-associated epistatic interactions, especially because of
the focus on a specific biochemical pathway with known func-
tion and strong connection to the etiology of the disease.
Although encouraging, these results should be replicated in
independent Ashkenazi Jewish patient and control cohorts
once larger sample sizes become available.
Notably, T2DM association was observed for a single
mitonuclear genotype combination involving NDUFC2 and
haplogroup HV (HV–CC). Because haplogroup HV is not de-
fined by mutations in the mtDNA-encoded interacting partner
of NDUFC2, ND4, the interference with disease association
likely occurred only through the other NDUFC2 variant,
valine 46. Previously, we observed coevolution and physical
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interaction between NDUFC2 and ND4 proteins, involving sev-
eral amino acid positions (Gershoni et al. 2010). Currently, we
are investigating the importance of these coevolving amino
acids for the physical interactions of NDUFC2 and ND4.
Nevertheless, it is worth noting that we currently cannot
rule out the attractive possibility that the observed association
of mitonuclear genotype with T2DM is due to inter-OXPHOS
complex interactions in the frame of OXPHOS super
complexes (Lapuente-Brun et al. 2013).
In conclusion, our results underline the importance of
mitonuclear interactions and coevolution in maintaining
OXPHOS function and the integrity of OXPHOS complex I.
We further showed that mutations in the code for a positively
selected amino acid in NDUFC2, a nuclear DNA-encoded
subunit of complex I, affected its interaction with an
mtDNA-encoded subunit of the complex. This finding stresses
the implication of the signature of natural selection on the
function of the protein. Because NDUFC2 was not present in
the bacterial complex I and similar to other “supernumerary
subunits” was added after the radiation of eukaryotes
(Gabaldon et al. 2005), our results lend further support to
the functional importance of the supernumerary subunits in
disease (Haack et al. 2012) and in complex I integrity (Mimaki
et al. 2011). Finally, we found that interfering with mitonu-
clear interactions, rather than with each genome alone, al-
tered the susceptibility to develop T2DM in Ashkenazi Jews.
In the future, larger samples sizes will allow increasing the
resolution of such disease associations from mtDNA
haplogroup clusters to haplogroups and possibly even to
haplotypes. It is worth noting that the results presented here
currently apply only to Ashkenazi Jews and should be
confirmed in other independent populations. Better under-
standing of the network of subunit interactions of mam-
malian complex I will allow testing for the functional
importance of more candidate mitonuclear interactions in
this complex not only during evolution but also in health
and in disease.
Supplementary Material
Supplementary figures S1–S3 and tables S1–S4 are available
at Genome Biology and Evolution online (http://www.gbe.
oxfordjournals.org/).
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